Genocea to Present at the 20th Annual Needham Virtual Healthcare Conference

Rhea-AI Summary

Genocea Biosciences (NASDAQ: GNCA) announced that CEO Chip Clark will present a corporate overview at the 20th Annual Needham Virtual Healthcare Conference on April 13, 2021, at 2:15 PM ET. A live webcast will be available on the company's investor relations website, with an archived version accessible for 90 days post-conference. Genocea focuses on developing personalized cancer immunotherapies using its ATLAS™ platform, which profiles patient T cell responses. Current programs include GEN-009, a neoantigen vaccine, and GEN-011, an adoptive T cell therapy.

CAMBRIDGE, Mass., April 06, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark, President and Chief Executive Officer, will present a corporate overview at the 20^th Annual Needham Virtual Healthcare Conference on Tuesday, April 13^th at 2:15 P.M. ET.

A live webcast of the presentation will be available "Events and Presentations" tab of the investor relations section of the Genocea website at http://ir.genocea.com. Following the conclusion of the conference, the presentation will remain archived on the Genocea website for approximately 90 days.

About Genocea Biosciences, Inc.
Genocea’s mission is to conquer cancer by developing personalized cancer immunotherapies in multiple tumor types. Our proprietary ATLAS™ platform comprehensively profiles each patient’s T cell responses to potential targets, or antigens, on that patient’s tumor. ATLAS zeroes in on both antigens that activate anti-tumor T cell responses and inhibitory antigens, Inhibigens™, that drive pro-tumor immune responses. We are advancing two ATLAS-enabled programs: GEN-009, our neoantigen vaccine for which we are conducting a Phase 1/2a clinical trial and GEN-011, our adoptive T cell therapy using neoantigen-targeted peripheral cells for which we are commencing a Phase 1/2a clinical trial. In addition to our two clinical programs, we are conducting research in several areas where we believe ATLAS could be a key tool in identifying meaningful therapies. To learn more, please visit https://www.genocea.com.

Investor Contact:
Dan Ferry
617-430-7576
daniel@lifesciadvisors.com

FAQ

What is Genocea Biosciences presenting at the Needham Virtual Healthcare Conference?

Genocea Biosciences will present a corporate overview at the conference on April 13, 2021, at 2:15 PM ET.

How can I watch Genocea's presentation at the Needham Conference?

You can watch the presentation live on Genocea's investor relations website under the 'Events and Presentations' tab.

What are the main programs Genocea is advancing?

Genocea is advancing two programs: GEN-009, a neoantigen vaccine, and GEN-011, an adoptive T cell therapy.

What is the purpose of the ATLAS™ platform used by Genocea?

The ATLAS™ platform profiles patient T cell responses to identify effective cancer immunotherapies.

How long will Genocea's presentation be available after the conference?

The presentation will remain archived on the Genocea website for approximately 90 days after the conference.